诺和诺德美股盘前跌超25%，公司下调全年业绩预期，减肥药Wegovy销售不及预期，此外，公司还任命了新的总裁兼首席执行官。

Group 1 - The company Novo Nordisk's stock fell over 25% in pre-market trading due to a downward revision of its full-year performance expectations [1] - Sales of the weight loss drug Wegovy were below expectations, contributing to the company's revised outlook [1] - The company appointed a new President and CEO, indicating a potential shift in leadership strategy [1]